Ahead of planned completion in June, German developer Formycon has published positive preliminary efficacy and safety data from its MAGELLAN-AMD Phase III clinical trial comparing the company’s proposed FYB203 aflibercept biosimilar to Regeneron’s Eylea (aflibercept) reference product.
Involving 434 participants, the randomized, double-masked, multicenter study is comparing the efficacy and safety of FYB203 to the world’s leading...
Welcome to Generics Bulletin
Create an account to read this article
Already a subscriber?